The European Commission wants to review procedures at the European Medicines Agency (EMA) to speed up new vaccines’ approval against more contagious and dangerous corona variants.
The way in which annual influenza vaccines, which are regularly adapted to changing influenza viruses, are now being assessed for rapid market authorization serves as a model for this.
The EU must also take “immediate” action to scale up the development and production of mutation vaccines, Brussels suggests.
“New variants of the virus are emerging rapidly, and we need to react to them even faster,” says chairman Ursula von der Leyen. The EU must “stay ahead of the curve.”
That is why the day-to-day EU administration proposes to pump money into bringing together researchers, industry and authorities to use all means against the new mutations and secure vaccines against them for the EU as soon as possible.